TOKYO & BOSTON--(BUSINESS WIRE)--Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ...

Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...

Bain Capital, a global private investment firm, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma ...

US private equity firm Bain Capital has agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit Mitsubishi Tanabe Pharma ... in the pharmaceuticals business”. The deal is expected ...

also known as Tanabe Pharma, is the pharmaceutical division of Mitsubishi Chemical Group. Under deal terms announced Friday, this pharma unit, which traces its origins to a Japanese business ...

TOKYO, Feb 7 (Reuters) - U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth ... investment in its core chemicals business as well as to help it reduce ...

As an independent company, Tanabe Pharma will continue to build on its legacy of medical innovation while developing new opportunities for growth through business development, licensing activities ...

US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion ... that it was exploring options for the business last year. "With the advancement of therapeutic ...

Private equity firm Bain Capital agreed to acquire Mitsubishi ... Sciences. Tanabe Pharma will continue to build on its legacy of medical innovation while boosting growth via business development ...

The U.S. investment company said Friday that it will buy Mitsubishi Tanabe Pharma for about 510 billion yen, equivalent to $3.37 billion.